Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis.

"Declarations Ethics approval and consent to participateTNBC specimens from three patients were collected after informed consent was obtained from all patients. This study was carried out according to the principles of the Helsinki Declaration and approved by the National Ethical Committee of Denmark (no. S-1906975). All animal experiments were approved by the Experimental Animal Committee of The Danish Ministry of Justice (2021–15-0201–00843). Consent for publicationNot applicable. Competing interestsAFK is a co-founder and an employee of Cytovac A/S, a biotechnology company that commercializes the ALECSAT therapy. AFK is co-inventors on a patent on ALECSAT and owns warrants and stock in Cytovac A/S. OGA, AFK and HJD are co-inventors of a patent application related to combined ALECSAT and anti-PDL1 therapy. The other authors declare no conflicts of interest. Competing interests AFK is a co-founder and an employee of Cytovac A/S, a biotechnology company that commercializes the ALECSAT therapy. AFK is co-inventors on a patent on ALECSAT and owns warrants and stock in Cytovac A/S. OGA, AFK and HJD are co-inventors of a patent application related to combined ALECSAT and anti-PDL1 therapy. The other authors declare no conflicts of interest."

"Funding Open access funding provided by University of Southern Denmark This work was supported by the Danish Cancer Society [grant to HJD], The National Board of Health (Empowering Immunotherapy in Denmark [grant to HJD], The Region of Southern Denmark Research Counsel [grant to HJD], CytoVac [grant to HJD], Kornerup Fonden [grant to HJD], Grosserer M. Brogaard og Hustrus Mindefond [grant to HJD and OGA]. Dagmar Marshalls Fond [grant to OGA], A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond [grant to OGA], Else og Mogens Wedell Wedellsborgs Fond [grant to OGA], Fabrikant Einar Willumsens Mindelegat [grant to OGA], Tornøes og Høyrups Fond [grant to OGA]."